Compass Pathways Plc
$ 10.85
-3.73%
28 Jul - close price
- Market Cap 1,520,879,000 USD
- Current Price $ 10.85
- High / Low $ 11.34 / 10.59
- Stock P/E N/A
- Book Value 2.42
- EPS -3.14
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.69 %
- 52 Week High 15.40
- 52 Week Low 3.92
About
COMPASS Pathways plc is a mental health care company in the United Kingdom and the United States. The company is headquartered in Cheshire, the United Kingdom.
Analyst Target Price
$24.47
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-24 | 2025-11-04 | 2025-07-31 | 2025-05-08 | 2025-02-27 | 2024-10-31 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.3 | -0.6065 | -0.38 | -0.41 | -0.42 | -0.63 | -0.56 | -0.56 | -0.55 | -0.53 | -0.67 | -0.62 |
| Estimated EPS | -0.31 | -0.3973 | -0.4 | -0.37 | -0.49 | -0.63 | -0.59 | -0.55 | -0.49 | -0.34 | -0.42 | -0.7 |
| Surprise | 0.01 | -0.2092 | 0.02 | -0.04 | 0.07 | 0 | 0.03 | -0.01 | -0.06 | -0.19 | -0.25 | 0.08 |
| Surprise Percentage | 3.2258% | -52.6554% | 5% | -10.8108% | 14.2857% | 0% | 5.0847% | -1.8182% | -12.2449% | -55.8824% | -59.5238% | 11.4286% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMPS
2026-07-28 21:40:04
Compass Pathways (CMPS) is positioned as a leader in regulated psilocybin therapy, with two successful Phase 3 trials and a rolling FDA submission for COMP360 targeting treatment-resistant depression. The company benefits from a substantial unmet need in depression, with additional long-term potential in PTSD and other indications. Despite increased competition following Lilly's move in the space, CMPS maintains a clinical lead and a strong cash runway.
2026-07-27 08:10:10
Compass Pathways PLC is a UK-based biotechnology company focused on developing evidence-based innovations in mental health, particularly for treatment-resistant depression (TRD) using its COMP360 psilocybin treatment. The company is currently in Phase III trials for TRD and Phase II for PTSD and anorexia nervosa. Its corporate profile details financial information, executive leadership, and significant institutional shareholdings.
2026-07-26 08:40:29
This article provides a brief overview of Compass Pathways PLC (CMPS) stock data, including its market cap, recent price, and performance. It notes that key valuation metrics like P/E, P/B, and P/CF ratios have not been disclosed by the company. The page appears to be a stub or a placeholder for more detailed analysis that is not yet available.
2026-07-25 19:40:29
This article provides an earnings forecast for Compass Pathways PLC (CMPS), including analyst ratings, price targets, and past and projected earnings per share (EPS). Based on 17 analysts, the stock has a "Buy" trend with a target price of USD 23.441, representing a potential upside of over 100%. The company's previous quarter EPS was USD -0.98, while the next quarter's EPS is expected to be USD -0.40.
2026-07-25 17:39:59
This article provides a detailed financial overview of Compass Pathways PLC (CMPS), including its stock performance, key financial figures, analyst ratings, and company information. CMPS is a biotechnology company focused on mental health, specifically developing its COMP360 psilocybin treatment for conditions like treatment-resistant depression. The stock is currently rated as a "Buy" by analysts, with a target price indicating significant upside potential, despite recent short-term declines in its share price.
2026-07-24 07:39:59
COMPASS Pathways (CMPS) recently released a post-hoc analysis of its COMP360 psilocybin treatment for PTSD, highlighting a low-intervention, standardized support model. This approach, characterized by minimal and largely non-directive support during administration sessions, could enhance the scalability and consistency of COMP360 across various conditions. The company's immediate focus remains on its Phase 3 TRD program and NDA submission, but this new data may influence long-term investment narratives regarding COMP360's potential in PTSD and its broader market adoption.
